King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Ahmad S. Alotaibi
Dr. Ahmad S. Alotaibi is a Consultant Hematologist specialising in Acute Leukaemia, bone marrow transplantation, and hematologic malignancies — serving international patients seeking expert acute leukemia specialist care in Riyadh, Saudi Arabia. MD Anderson-trained, he is a prolific researcher with an extensive publication record covering AML, ALL, and stem cell transplantation outcomes.
- Consultant in Hematology and Bone Marrow Transplantation with MD Anderson Cancer Center fellowship training
- Active researcher with an extensive portfolio of peer-reviewed research works
- Key investigator on landmark 363-patient Saudi AML genomic study using WGS
- Published on T-ALL AYA protocol with 71% overall survival and 62% disease-free survival
- Active in BPDCN, Philadelphia-positive AML, and CML-in-pregnancy research
Qualifications & Credentials
Medical Degrees
- MBBS — Bachelor of Medicine and Bachelor of Surgery
- Internal Medicine Residency
Fellowships & Special Training
- Fellowship — Adult Hematology and Hematologic Malignancies
- Clinical Fellowship — The University of Texas MD Anderson Cancer Center, Houston, USA
- Fellowship — Bone Marrow Transplantation
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) — Consultant
Areas of Expertise
Major Conditions Treated
- Acute Myeloid Leukaemia (AML)
- Acute Lymphoblastic Leukaemia (ALL)
- Philadelphia-Positive Acute Leukaemia
- T-Cell Acute Lymphoblastic Leukaemia (T-ALL)
- Chronic Myeloid Leukaemia (CML)
- Chronic Lymphocytic Leukaemia (CLL)
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Myelodysplastic Syndrome (MDS)
- Sickle Cell Disease (Adult, for transplant)
- CML in Pregnancy
Sub-specialties
- Acute Leukaemia Management: Expert in AML, ALL, and Philadelphia-positive leukaemia treatment including tyrosine kinase inhibitors, pediatric-inspired AYA protocols, and allogeneic transplant — a trusted acute leukaemia specialist in Riyadh for international patients.
- Bone Marrow Transplantation: Allogeneic stem cell transplant including matched sibling, matched unrelated, and haplo-identical donor transplants with post-transplant cyclophosphamide.
- Rare Hematologic Malignancies: Diagnostic and therapeutic expertise in BPDCN and rare leukaemia subtypes through multidisciplinary approaches.
Advanced Procedures & Treatments
- Induction, Consolidation, and Maintenance Chemotherapy for Acute Leukaemia
- Allogeneic Haematopoietic Stem Cell Transplantation
- Haplo-Identical Donor Transplantation with Post-Transplant Cyclophosphamide
- Tyrosine Kinase Inhibitor Therapy (Imatinib, Dasatinib, Ponatinib)
- Blinatumomab and Targeted Immunotherapies
- Pediatric-Inspired AYA-15 Protocol for Acute Leukaemia
- Whole Genome Sequencing (WGS) and NGS-Based Risk Stratification
- Bone Marrow Biopsy and Aspiration
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh — Consultant Hematology and BMT, Department of Hematology, Stem Cell Transplantation, and Cellular Therapy, Cancer Center of Excellence (Present)
Past Affiliations
- The University of Texas MD Anderson Cancer Center, Houston, USA — Clinical Fellow (Past)
Academic & Research Roles
- Investigator — Saudi AML Genomic Landscape Study (KFSHRC)
- Co-investigator — Saudi T-ALL/LBL-AYA Protocol Research
- Contributor — KFSHRC Hematologic Malignancy Tumour Board
Key Achievements
- Extensive peer-reviewed research record in hematology and stem cell transplantation
- Key investigator on 363-patient Saudi AML molecular characterisation study using PCR and NGS
- Co-author on 786-patient whole genome sequencing AML study — first of its kind in Middle East
- Co-author on T-ALL AYA protocol demonstrating 71% OS, 62% DFS, 49.6% EFS at 5 years
- Contributor to BPDCN diagnostic consensus recommendations for GCC countries
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Hematology (ASH)
- European Society for Blood and Marrow Transplantation (EBMT)
- Saudi Society of Hematology
Research & Publications
Published Papers (Selected)
- Alfaham MS, Ahmed SO, ..., Alotaibi A, et al. "Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population." Blood. 2024;144(Suppl 1):4231.
- Alfaham M, Alotaibi AS, Rasheed W, et al. "Molecular Characterisation and Outcomes of 363 Adolescent and Young Adults with AML in Saudi Arabia Risk Stratified By PCR and NGS-Based Testing." Blood. 2023.
- Hanbali A, Kotb A, ..., Alotaibi A, et al. "Improved survival of adolescents and young adults patients with T-cell acute lymphoblastic leukemia." Int J Hematol Oncol. 2023;12(1):IJH42. DOI: 10.2217/ijh-2022-0005.
- Alotaibi AS, et al. "The Road Not Taken: Exploring Non-Transplant Options in De Novo Philadelphia Positive Acute Myeloid Leukemia." (Review article).
- Alotaibi AS, et al. "A Multidisciplinary Approach to Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Practical Recommendations and Insights from Countries of the Gulf Cooperation Council."
Ongoing Research & Clinical Interests
- AML genomic landscape in Middle Eastern populations
- Philadelphia-positive AML and alternative non-transplant strategies
- Pediatric-inspired protocols in AYA acute leukaemia
- CML management during pregnancy
- Sickle cell disease HSCT in adults
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Hematology / Leukaemia Consultation | ₹2,500 – ₹6,000 | $30 – $72 |
| Acute Leukaemia Induction Chemotherapy | ₹2,00,000 – ₹7,50,000 | $2,400 – $9,000 |
| Tyrosine Kinase Inhibitors (monthly) | ₹15,000 – ₹1,50,000 | $180 – $1,800 |
| Allogeneic Stem Cell Transplant | ₹25,00,000 – ₹45,00,000 | $30,000 – $54,000 |
| Haplo-Identical Transplant (with PTCy) | ₹22,00,000 – ₹38,00,000 | $26,500 – $45,500 |
| NGS Molecular Panel / WGS | ₹50,000 – ₹2,00,000 | $600 – $2,400 |
| Bone Marrow Biopsy | ₹10,000 – ₹25,000 | $120 – $300 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Ahmad S. Alotaibi use in Acute Leukemia treatment?
Dr. Ahmad S. Alotaibi uses whole genome sequencing (WGS) and next-generation sequencing (NGS) risk stratification, allogeneic and haplo-identical stem cell transplant with post-transplant cyclophosphamide, tyrosine kinase inhibitors (imatinib, dasatinib, ponatinib), blinatumomab, pediatric-inspired AYA-15 protocols, and evidence-based induction regimens. Virtual consultations are available for international patients. Contact Cancer Rounds for a detailed technology overview.
2. What conditions does Dr. Ahmad S. Alotaibi specialize in treating?
Dr. Ahmad S. Alotaibi specialises in acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), Philadelphia-positive leukaemia, T-cell ALL, chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and myelodysplastic syndrome. International patients seek his expertise as an acute leukaemia specialist in Riyadh, Saudi Arabia.
3. How do I book an appointment with Dr. Ahmad S. Alotaibi?
Appointments with Dr. Ahmad S. Alotaibi can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Ahmad S. Alotaibi?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Ahmad S. Alotaibi, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Ahmad S. Alotaibi offer second opinions for Acute Leukemia cases?
Yes. Second opinion consultations for Acute Leukemia can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with an expert acute leukaemia specialist in Riyadh, Saudi Arabia.
